/SNSE
SNSE Stock - Sensei Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$8.86-2.85%
$0.26 (-2.85%) • Dec 19
42
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-37.9%upside
Target: $5.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNSE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.77 – $8.95
TARGET (TP)$5.50
STOP LOSS$8.15
RISK/REWARD1:-4.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.31
52W High$18.35
52W Low$5.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-551,000 | $-571,000 | $-1,808,000 | $-685,000 | $-209,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-31,663,000 | $-37,064,000 | $-49,120,000 | $-37,482,000 | $-19,451,000 |
| Net Income | $-30,157,000 | $-34,101,000 | $-48,588,000 | $-36,794,000 | $-20,100,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.20 | $-1.22 | $-1.58 | $-1.33 | $-0.67 |
Company Overview
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↓ 43.6% Downside
Now
$5
Low
$5
Average
$5
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | H.C. Wainwright | Resumed | Buy | $5 |
| May 14th 2024 | Stephens | Initiation | Overweight | $5 |
Earnings History & Surprises
SNSEBeat Rate
47%
Last 19 quarters
Avg Surprise
-2.3%
EPS vs Estimate
Beats / Misses
9/8
2 met exactly
Latest EPS
$-3.62
Q4 2025
EPS Surprise History
Q1 24
+6.3%
$-0.30vs$-0.32
Q2 24
-10.3%
$-0.32vs$-0.29
Q3 24
-12.0%
$-0.28vs$-0.25
Q4 24
+6.5%
$-0.29vs$-0.31
Q1 25
0.0%
$-5.40vs$-5.40
Q2 25
-28.6%
$-5.40vs$-4.20
Q3 25
+36.9%
$-3.91vs$-6.20
Q4 25
+11.9%
$-3.62vs$-4.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-4.81 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-4.11 | $-3.62 | +11.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-6.20 | $-3.91 | +36.9% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-4.20 | $-5.40 | -28.6% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-5.40 | $-5.40 | 0.0% | = MET |
Q4 2024 | Nov 14, 2024 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.25 | $-0.28 | -12.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.29 | $-0.32 | -10.3% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.28 | $-0.28 | 0.0% | = MET |
Q3 2023 | Aug 3, 2023 | $-0.32 | $-0.31 | +3.1% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.35 | $-0.33 | +5.7% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.37 | $-0.44 | -18.9% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.35 | $-0.40 | -14.3% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.34 | $-0.29 | +14.7% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.25 | $-0.32 | -28.0% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-0.33 | $-0.42 | -27.3% | ✗ MISS |
Latest News
Sensei Biotherapeutics Q3 EPS $(3.62) Beats $(4.11) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 12:38 PM
HC Wainwright & Co. Downgrades Sensei Biotherapeutics to Neutral
➖ NeutralBenzinga•Oct 30, 2025, 04:27 PM
Sensei Biotherapeutics Expects To Implement Workforce Reduction To Preserve Cash As Part Of Its Strategic Review
📉 NegativeBenzinga•Oct 30, 2025, 01:11 PM
Sensei Biotherapeutics Board Determines To Discontinue Development Of Solnerstotug And Initiate Comprehensive Review Of Strategic Alternatives To Maximize Shareholder Value
📉 NegativeBenzinga•Oct 30, 2025, 01:10 PM
Trading Halt: Halted at 8:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 30, 2025, 12:55 PM
Sensei Biotherapeutics Releases Results From The Phase 1/2 Dose Expansion Study Of Solnerstotug Presented At ESMO 2025. The Data Addressed The Critical Challenge Of Secondary Resistance To Immune Checkpoint Inhibitors, Where Treatment Success Rates Are Typically Below 5%
📈 PositiveBenzinga•Oct 17, 2025, 12:16 PM
Frequently Asked Questions about SNSE
What is SNSE's current stock price?
Sensei Biotherapeutics, Inc. (SNSE) is currently trading at $8.86 per share. The stock has moved -2.85% today.
What is the analyst price target for SNSE?
The average analyst price target for SNSE is $5.50, based on 1 analyst.
What sector is Sensei Biotherapeutics, Inc. in?
Sensei Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SNSE's market cap?
Sensei Biotherapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does SNSE pay dividends?
No, Sensei Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to SNSE for comparison